This is a promotional poster produced and fully funded by Bayer plc for UK healthcare professionals only. Prescribing information and adverse event reporting information for EYLEA® (aflibercept) 2 mg and EYLEA 8 mg can be accessed via the link or QR code located at the bottom of this document.

EYLEA® 8mg
(aflibercept 114.3mg/mL, solution for injection)

EYLEA® (aflibercept) 8 mg real-world evidence

12-month real-world outcomes in previously treated patients with nAMD

University Hospitals of Leicester NHS Trust

These data are from real patients. Individual results may vary.

Study design:
Observational, prospective, case-controlled audit evaluated outcomes in 126 previously treated eyes with nAMD. Outcomes evaluated were best corrected visual acuity, central retinal thickness and treatment intervals at 12 months after switching to EYLEA 8 mg.

Patients were considered as suboptimal responders to previous treatment administered according to a T&E regimen. Patients unable to extend beyond 8 weeks due to disease activity were defined as suboptimal responders. All patients received a minimum of four injections with EYLEA 2 mg or faricimab before switching to EYLEA 8 mg.
Previous treatment: 55.8% EYLEA 2 mg; 44.2% faricimab.

Patient demographics

Eyes, N	126
Mean age, years	79
Female, %	62.7

Interval extension with EYLEA 8 mg at Month 12

Treatment interval at Month 12



Proportion of patients who achieved ≥q10 intervals at Month 12 with EYLEA 8 mg



EYLEA 2 mg
Previous treatment
(n=67)

Faricimab
Previous treatment
(n=53)

Proportion of patients who achieved ≥q12 intervals at Month 12 with EYLEA 8 mg

EYLEA 2 mg
Previous treatment
(n=67)

Faricimab
Previous treatment
(n=53)

~50% of patients achieved intervals of **≥q12 regardless of previous treatment**

Sustained fluid control
with EYLEA 8 mg

Change in CRT over time



Maintained vision
with EYLEA 8 mg

Change in BCVA over time



Patients maintained fluid control and vision regardless of previous treatment

During the audit, two cases of submacular haemorrhage and one case of endophthalmitis were observed. The endophthalmitis was successfully treated with intravitreal antibiotics, resulting in full recovery.

Please see the EYLEA 8 mg Summary of Product Characteristics for full details of the safety profile.
*Statistical analysis using the paired t-test was performed for whole cohort analysis.

Abbreviations:
BCVA, best corrected visual acuity; **CRT**, central retinal thickness;
logMAR, logarithm of the minimum angle of resolution;
nAMD, neovascular age-related macular degeneration; **qX**, every X weeks; **T&E**, treat-and-extend.

Reference:
Bayer UK Data on File_PP-EYL_8mg-GB-0882_January 2026.

May 2026 | PP-EYL_8mg-GB-1041

Prescribing information and adverse event reporting information for EYLEA® (aflibercept) is available via the QR code on the right.
Either click **here** or scan the QR code for prescribing information and adverse event reporting information.
For direct access to this prescribing information, please ensure your device's browser settings have automatic PDF download enabled.